Daiichi Sankyo Company, Limited (4568.T)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Hiroyuki Okuzawa
|
President, CEO & Representative Director | 152M | -- | 1962 |
|
Mr. Takashi Matsumoto
|
Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director | 67M | -- | 1964 |
|
Mr. Joseph Kenneth Keller
|
Head of Oncology Business Unit & Global Oncology Business and Director | 501M | -- | 1963 |
|
Mr. Tomohiro Kodama
|
Senior Executive Officer, Head of Global Corporate Planning & Management and CFO | -- | -- | -- |
|
Tetsuya Ohira
|
Corporate Officer, Head of Business Transformation & CTO | -- | -- | -- |
|
Naoto Tsukaguchi
|
Senior Executive Officer, Head of Global Legal & IP, GC | -- | -- | -- |
|
Matt Allegrucci
|
Head of Global Compliance & Risk Management and Chief Compliance Officer | -- | -- | -- |
|
Mr. Joji Nakayama
|
Senior Adviser | 154M | -- | 1950 |
|
Mr. Stuart Mackey J.D.
|
Global Head of Business Development & Director | -- | -- | -- |
|
Thierry Gruson
|
Head of Global Oncology Marketing | -- | -- | -- |
Daiichi Sankyo Company, Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 20,171
Description
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
Corporate Governance
Upcoming Events
October 30, 2026 at 6:30 AM UTC
Daiichi Sankyo Company, Limited Earnings Date
March 30, 2027 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
Recent Events Information Not Available
